What Analysts Are Saying About Axsome Therapeutics Stock
Portfolio Pulse from Benzinga Insights
Axsome Therapeutics (NASDAQ:AXSM) has been evaluated by 14 analysts over the last three months, showing a shift towards more bullish sentiments. The average 12-month price target for AXSM has risen to $123.57, marking a 16.58% increase from the previous target. Analysts' actions, including rating adjustments and price target changes, reflect their evolving views on the company's performance and market conditions. Axsome Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing therapies for CNS disorders. Despite its positive revenue growth rate of 193.5%, the company's financial indicators such as net margin, ROE, and ROA remain below industry averages.
February 27, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axsome Therapeutics has seen a positive shift in analyst sentiment, with an increased average price target of $123.57. The company's significant revenue growth contrasts with its below-average financial health indicators.
The increase in the average price target and the shift towards more bullish ratings by analysts suggest a positive short-term outlook for AXSM's stock price. However, investors should also consider the company's financial health indicators, which may impact its long-term performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100